<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhu Z</submitter><funding>NCI NIH HHS</funding><funding>National Institutes of Health</funding><funding>NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>e2203718</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9875608</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(3)</volume><pubmed_abstract>STING is an innate immune sensor for immune surveillance of viral/bacterial infection and maintenance of an immune-friendly microenvironment to prevent tumorigenesis. However, if and how STING exerts innate immunity-independent function remains elusive. Here, the authors report that STING expression is increased in renal cell carcinoma (RCC) patients and governs tumor growth through non-canonical innate immune signaling involving mitochondrial ROS maintenance and calcium homeostasis. Mitochondrial voltage-dependent anion channel VDAC2 is identified as a new STING binding partner. STING depletion potentiates VDAC2/GRP75-mediated MERC (mitochondria-ER contact) formation to increase mitochondrial ROS/calcium levels, impairs mitochondria function, and suppresses mTORC1/S6K signaling leading to</pubmed_abstract><journal>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</journal><pubmed_title>STING Suppresses Mitochondrial VDAC2 to Govern RCC Growth Independent of Innate Immunity.</pubmed_title><pmcid>PMC9875608</pmcid><funding_grant_id>R01GM102413</funding_grant_id><funding_grant_id>R01 CA243543</funding_grant_id><funding_grant_id>R35 GM141833</funding_grant_id><funding_grant_id>P30 CA016086</funding_grant_id><funding_grant_id>R35GM141833</funding_grant_id><funding_grant_id>R01 GM083024</funding_grant_id><funding_grant_id>R01 GM102413</funding_grant_id><funding_grant_id>R01GM083024</funding_grant_id><pubmed_authors>Cloer EW</pubmed_authors><pubmed_authors>Zhu Z</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Liu P</pubmed_authors><pubmed_authors>Zhou X</pubmed_authors><pubmed_authors>Cook JG</pubmed_authors><pubmed_authors>Dotti G</pubmed_authors><pubmed_authors>Mei L</pubmed_authors><pubmed_authors>Simon JM</pubmed_authors><pubmed_authors>Tan X</pubmed_authors><pubmed_authors>Major MB</pubmed_authors><pubmed_authors>Hepperla AJ</pubmed_authors><pubmed_authors>Du H</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>STING Suppresses Mitochondrial VDAC2 to Govern RCC Growth Independent of Innate Immunity.</name><description>STING is an innate immune sensor for immune surveillance of viral/bacterial infection and maintenance of an immune-friendly microenvironment to prevent tumorigenesis. However, if and how STING exerts innate immunity-independent function remains elusive. Here, the authors report that STING expression is increased in renal cell carcinoma (RCC) patients and governs tumor growth through non-canonical innate immune signaling involving mitochondrial ROS maintenance and calcium homeostasis. Mitochondrial voltage-dependent anion channel VDAC2 is identified as a new STING binding partner. STING depletion potentiates VDAC2/GRP75-mediated MERC (mitochondria-ER contact) formation to increase mitochondrial ROS/calcium levels, impairs mitochondria function, and suppresses mTORC1/S6K signaling leading to</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2026-05-28T11:32:05.823Z</modification><creation>2025-04-07T03:19:17.023Z</creation></dates><accession>S-EPMC9875608</accession><cross_references><pubmed>36445063</pubmed><doi>10.1002/advs.202203718</doi></cross_references></HashMap>